In North America, key drivers include investments in digital health, favourable policies supporting respiratory care, and high ecosystem maturity, contributing to a regional share of around 25%. Europe, with a share of approximately 20%, is driven by regulatory support, reimbursement policies, and a strong pharmaceutical industry. Latin America, with around 10% share, is driven by increasing adoption of manual nebulisers, growing demographics, and improving infrastructure. The Middle East & Africa, with around 10% share, is driven by government initiatives to improve healthcare infrastructure and increasing awareness about respiratory diseases.